These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20442535)

  • 1. Tyrosine kinase inhibitors and acute pancreatitis.
    Pezzilli R; Corinaldesi R; Morselli-Labate AM
    JOP; 2010 May; 11(3):291-3. PubMed ID: 20442535
    [No Abstract]   [Full Text] [Related]  

  • 2. Tyrosine kinase inhibitor induced pancreatitis.
    Sevin A; Chen A; Atkinson B
    J Oncol Pharm Pract; 2013 Sep; 19(3):257-60. PubMed ID: 23034406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
    J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract]   [Full Text] [Related]  

  • 6. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?
    Winn SK; Ellis S; Savage P; Sampson S; Marsh JE
    Nephrol Dial Transplant; 2009 Feb; 24(2):673-5. PubMed ID: 19039026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
    Saylor PJ; Reid TR
    J Clin Oncol; 2007 Aug; 25(23):3544-6. PubMed ID: 17687160
    [No Abstract]   [Full Text] [Related]  

  • 8. Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.
    Miksad RA; Lai KC; Stein MC; Healy ME; Rojas R; Krajewski KM; Zhu AX
    J Gastrointest Cancer; 2009; 40(3-4):119-22. PubMed ID: 19894033
    [No Abstract]   [Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine.
    de Groot JW; Links TP; van der Graaf WT
    Ann Oncol; 2006 Nov; 17(11):1719-20. PubMed ID: 16731538
    [No Abstract]   [Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
    Lenihan DJ
    J Clin Oncol; 2008 Nov; 26(32):5154-5. PubMed ID: 18838702
    [No Abstract]   [Full Text] [Related]  

  • 11. [Leg ulcers occurring under tyrosine kinase inhibitor therapy (sunitinib, nilotinib)].
    Roger A; Sigal ML; Bagan P; Sin C; Bilan P; Dakhil B; Fargeas C; Couffinhal JC; Mahé E
    Ann Dermatol Venereol; 2017 Jan; 144(1):49-54. PubMed ID: 27527566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma.
    Arnaud L; Schartz NE; Bousquet G; Sarandi F; Verola O; Madelaine I; Kerob D; Lebbe C
    J Clin Oncol; 2008 Mar; 26(9):1569-71. PubMed ID: 18349416
    [No Abstract]   [Full Text] [Related]  

  • 13. Blue toe syndrome and sunitinib.
    Postema PG; Regeer MV; van der Valk PR; Stroes ES; Richel DJ
    Int J Clin Oncol; 2011 Oct; 16(5):574-6. PubMed ID: 21136131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.
    Khakoo AY; Kassiotis CM; Tannir N; Plana JC; Halushka M; Bickford C; Trent J; Champion JC; Durand JB; Lenihan DJ
    Cancer; 2008 Jun; 112(11):2500-8. PubMed ID: 18386829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyoderma gangrenosum with the use of sunitinib.
    Nadauld LD; Miller MB; Srinivas S
    J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
    [No Abstract]   [Full Text] [Related]  

  • 16. [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].
    Ahlman H; Nilsson O; Nilsson B
    Lakartidningen; 2009 Dec 9-21; 106(50-51):3424-9. PubMed ID: 20180446
    [No Abstract]   [Full Text] [Related]  

  • 17. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
    Patel TV; Morgan JA; Demetri GD; George S; Maki RG; Quigley M; Humphreys BD
    J Natl Cancer Inst; 2008 Feb; 100(4):282-4. PubMed ID: 18270341
    [No Abstract]   [Full Text] [Related]  

  • 18. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
    Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
    Thyroid; 2009 May; 19(5):539-40. PubMed ID: 19416001
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
    Reichardt P; Blay JY; Gelderblom H; Schlemmer M; Demetri GD; Bui-Nguyen B; McArthur GA; Yazji S; Hsu Y; Galetic I; Rutkowski P
    Ann Oncol; 2012 Jul; 23(7):1680-7. PubMed ID: 22357255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
    Kang YK; Ryu MH; Yoo C; Ryoo BY; Kim HJ; Lee JJ; Nam BH; Ramaiya N; Jagannathan J; Demetri GD
    Lancet Oncol; 2013 Nov; 14(12):1175-82. PubMed ID: 24140183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.